Format

Send to

Choose Destination
See comment in PubMed Commons below
An Pediatr (Barc). 2010 Dec;73(6):327-33. doi: 10.1016/j.anpedi.2010.09.001. Epub 2010 Oct 15.

[Early administration of erythropoietin in the extreme premature, a risk factor for retinopathy of prematurity?].

[Article in Spanish]

Author information

  • 1ICGON, Hospital Clínico, Universidad de Barcelona, España. jfiguer@clinic.ub.es

Abstract

INTRODUCTION:

Erythropoietin (EPO) stimulates angiogenesis and may favour the appearance of retinopathy of prematurity (ROP). The objective was to determine if EPO+Fe administered from the 5th day of life could be an independent risk factor for ROP appearance and its severity.

PATIENTS AND METHOD:

The study included 718 preterm newborns with a birth weight ≤1,500g or a gestational age ≤32 weeks (and 6 days), admitted between 2001 and 2008. During these years, the target SaO₂ was between 88% and 93%. EPO treatment began at 5-7 days of life, with a dose of 250 UI/Kg, 3 times a week, subcutaneously, together with Fe, 5-6mg/kg/day, both until 34 weeks of corrected age or discharge.

RESULTS:

A total of 493 preterms (68.7%) did not have ROP, 139 (19.4%) had a grade 1 ROP, 50 (7.0%) a grade 2 ROP and 36 (5.0%) a grade 3 ROP. Laser therapy was required by 27 severe ROP was associated with lower birth weight and gestational age, more neonatal morbidity and a more aggressive treatment (duration of oxygen supplements or mechanical ventilation, number of blood transfusions). Risk factors independently and significantly associated with any ROP grade were: lower birth weight, no caesarean section, EPO administration and need for blood transfusion. EPO administration increased the risk of ROP by 2.4, but this only happened in case of grade 1 ROP (OR: 5.50).

CONCLUSIONS:

EPO+Fe administration is associated and perhaps stimulates the appearance of grade 1 ROP.

Copyright © 2010 Asociación Española de Pediatría. Published by Elsevier Espana. All rights reserved.

[PubMed - indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Ediciones Doyma, S.L.
    Loading ...
    Write to the Help Desk